Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review

Abstract

\n\nDue to the increasing prevalence of cancer and the inadequacy of current\ntherapies, the development of novel antitumor pharmaceutics with higher efficacies and lower adverse\neffects is considered a fundamental tenet of contemporary cancer management.\nPoly-Ethylene-Glycol (PEG) attachment is a novel pharmaceutical technology to improve the efficacy\nand safety of chemotherapies. Etirinotecan Pegol (EP), also known as NKTR-102, is the PEGylated\nform of Irinotecan (CPT-11), which causes cancer cell apoptosis by inhibiting the\ntopoisomerase I enzyme.\n\n\n\nThe present study reviews and evaluates various reports of the EP’s anti-tumor activity\nin various cancers.\n\n\n\nStudies were identified using the Scopus database, with no exclusions. The search\nterms included Etirinotecan Pegol and NKTR-102, which yielded 125 articles (66 and 59 articles,\nrespectively). In addition, the clinicaltrials.gov website was used to find ongoing studies, which resulted\nin the addition of two studies.\n\n\n\nSubsequently, we excluded studies that were published in languages\nother than English, duplicate articles, and studies with no data.\n\n\n\n This systematic review clarifies that EP possesses numerous advantages over many other\nmedications, such as safety, efficacy, increased half-life, increased health-related quality of life, increased\noverall survival, increased progression-free survival, and decreasing the adverse events in\nthe treatment of various cancers.\n\n\n\nTherefore, Etirinotecan Pegol may represent a major contribution to the treatment of\nvarious cancers in the future.\n